Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonoma PharmaceuticalsFRA:O8Z 34 PB Ratio is 1.83 as of Jul. 29, 2026, which is 61% above its 10-year median of 1.14. GuruFocus rates FRA:O8Z with a GF Score™ of 34/100 and a GF Value™ of €6.04. The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Sonoma Pharmaceuticals ranks better than 86.97% on this metric.
Sonoma Pharmaceuticals Inc stock PB Ratio (=0.66) is close to 2-year low of 0.61.
The historical rank and industry rank for Sonoma Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:O8Z'
s PB Ratio Range Over the Past 10 Years
Min: 0.13 Med: 1.14 Max: 3.51
Current: 0.66
During the past 13 years, Sonoma Pharmaceuticals's highest PB Ratio was 3.51. The lowest was 0.13. And the median was 1.14.
FRA:O8Z's PB Ratio is ranked better than 86.97% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs FRA:O8Z: 0.66
During the past 12 months, Sonoma Pharmaceuticals's average Book Value Per Share Growth Rate was -36.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -62.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -54.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -45.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sonoma Pharmaceuticals was 46.60% per year. The lowest was -716.80% per year. And the median was -34.50% per year.
Back to Basics: PB Ratio
Sonoma Pharmaceuticals (FRA:O8Z) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sonoma Pharmaceuticals (FRA:O8Z) has a PB Ratio of 1.83 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sonoma Pharmaceuticals and its competitors. This is 61% above median its historical median of 1.14. Over the past decade, Sonoma Pharmaceuticals' PB Ratio has ranged from 0.13 to 3.51. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #120 out of 921 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Sonoma Pharmaceuticals' PB Ratio too high?
Sonoma Pharmaceuticals' current PB Ratio of 1.83 is 61% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 3.51. The Drug Manufacturers industry median PB Ratio is 1.90. Sonoma Pharmaceuticals' value of 1.83 is 3.7% below this industry median. Based on the distribution chart, Sonoma Pharmaceuticals ranks #120 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' PB Ratio compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #120 out of 921 companies for PB Ratio. This places Sonoma Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. Sonoma Pharmaceuticals' value of 1.83 is 3.7% below this benchmark. Historically, Sonoma Pharmaceuticals' own PB Ratio has ranged from 0.13 to 3.51 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 1.90, Sonoma Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonoma Pharmaceuticals's current PB Ratio of 1.83 is 3.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current PB Ratio is 1.83, which is 61% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current PB Ratio of 1.83. The stock's GF Value™ is €6.04, compared to a current price of €2.72 — trading 55% below its estimated fair value. The current PB Ratio is 1.83, which is 61% above median its 10-year median of 1.14 and 3.7% below the Drug Manufacturers industry median of 1.90. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current PB Ratio is 1.83 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.
Key valuation signals for FRA:O8Z:
PB Ratio: 1.83 (61% above median its 10-year median of 1.14)
GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
Industry Position: 3.7% below the Drug Manufacturers median (#120 of 921)
No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score
Get the complete analysis for FRA:O8Z
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O8Z has been successfully added to your 
